Jiangsu Hengrui Medicine
600276.SS
#434
Rank
HK$428.36 B
Marketcap
HK$64.54
Share price
-1.46%
Change (1 day)
35.66%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2025 (TTM): HK$1.00

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is HK$1.00. In 2024 the company made an earnings per share (EPS) of HK$1.07 an increase over its 2023 EPS that were of HK$0.75.

EPS history for Jiangsu Hengrui Medicine from 2000 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$1.00-6.49%
2024HK$1.0742.43%
2023HK$0.758.77%
2022HK$0.69-20.62%
2021HK$0.87-26.59%
2020HK$1.1927.24%
2019HK$0.9328.41%
2018HK$0.7320.04%
2017HK$0.6031.21%
2016HK$0.4611.46%
2015HK$0.4136.27%
2014HK$0.3019.77%
2013HK$0.2518.05%
2012HK$0.2123.9%
2011HK$0.1726.9%
2010HK$0.1412.37%
2009HK$0.1256.6%
2008HK$0.077569.18%
2007HK$0.07104114.48%
2006HK$0.0331264.83%
2005HK$0.0201035.55%
2004HK$0.0148329.73%
2003HK$0.0114319.86%
2002HK$0.009535-2.71%
2001HK$0.0098001.02%
2000HK$0.009701